The Globe and Mail reports in its Thursday edition that Echelon Capital Markets analyst Rob Goff continues to rate Think Research "speculative buy." The Globe's David Leeder writes in the Eye On Equities column that Mr. Goff gave his share target a 30-cent trim to 80 cents. Analysts on average target the shares at 83 cents. Mr. Goff says in a note: "While we are encouraged with another record quarter from Think and the broader trajectory pointing up, we are mindful of the moderate near-term headwinds around the breached debt covenant and softness across the company's clinical research/services segments. Unfortunately, that softness, particularly at Clinic360 (a non-core asset), has coincided with a challenged healthcare clinic environment (though less so on the private pay side, comprising most of the segment's revenues) where it would likely be difficult for Think to realize fair value for the asset at a time when it could use the liquidity to pay down debt. With the company's contract research organization (CRO) BioPharma, the asset has underperformed since its announced acquisition in July, 2021. ... We would anticipate near-term material announcements to come over the remaining four months of 2023."